"Dr. Chari On Challenges In Sequencing Agents For Multiple Myeloma" - Ajai Chari, MD
Ajai Chari, MD, associate professor of medicine, hematology, medical oncology at the Icahn School of Medicine at Mount Sinai, director of clinical research in the multiple myeloma program and associate director of clinical research at the Mount Sinai Cancer Clinical Trials Office, discusses challenges in sequencing agents for patients with multiple myeloma. According to Dr. Chari, the use of daratumumab (Darzalex) induction therapy and ixazomib (Ninlaro) in the maintenance setting are making patients refractory to a different drug class. Many researchers are investigating how quickly chimeric antigen receptor (CAR) T-cell therapy can be given to patients based on the risk value, explains Dr. Chari.
- Ajai Chari, MD, Associate Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office
The Mount Sinai Hospital Ranked Among Top in the Nation by U.S. News & World Report®
Jul 29, 2025 View All Press Releases
Mount Sinai Researchers Engineer Rare Immune Cells to Create Powerful New Cancer Vaccine
Jul 21, 2025 View All Press Releases
Mount Sinai’s Cancer Science in the Spotlight at 2025 ASCO
May 29, 2025 View All Press Releases
Mount Sinai Study Advances Understanding of Personalized Vaccines for Bladder Cancer
May 12, 2025 View All Press Releases
Mount Sinai Researchers Discover How Melanoma May Spread to the Brain
Apr 30, 2025 View All Press Releases
Mount Sinai Showcases Innovative Cancer Research at 2025 AACR Annual Meeting in Chicago
Apr 24, 2025 View All Press Releases